8-OH-DPAT (8-Hydroxy-DPAT)

Catalog No.S8447

For research use only.

8-OH-DPAT (8-Hydroxy-DPAT) is a kind of classic 5-HT1A agonist with the pIC50 of 8.19. It has a selectivity of almost-1000 fold for a subtype of the 5-HT1 binding site; Its biological half-life is 1.5 hous.

8-OH-DPAT (8-Hydroxy-DPAT) Chemical Structure

CAS No. 78950-78-4

Purity & Quality Control

Choose Selective 5-HT Receptor Inhibitors

Other 5-HT Receptor Products

Biological Activity

Description 8-OH-DPAT (8-Hydroxy-DPAT) is a kind of classic 5-HT1A agonist with the pIC50 of 8.19. It has a selectivity of almost-1000 fold for a subtype of the 5-HT1 binding site; Its biological half-life is 1.5 hous.
Targets
5-HT1A [1]
(Cell-free)
8.19(pIC50)
In vitro

The drug is only weakly effective at 5-HT1B subtype, the pIC50 being 5.42 ± 0.08 (n = 5). Since 8-OH-DPAT has no effect on 5-HT1B binding at concentrations lower than 100 nM[1]. 8-OH-DPAT is able to reduce the accumulation of both autophagic-derived and photoreceptor outer segment-derived lipofuscin, increase antioxidant protection and reduce oxidative damage in cultured human RPE cells[4].

In vivo Intravenous administration of the selective 5-HT1A-receptor agonist 8-OH-DPAT rapidly reverses the hypotensive and bradycardic responses established during severe hemorrhage with relatively little variability. 8-OH-DPAT is relatively lipophilic and readily crosses the blood-brain barrier[3].

Protocol (from reference)

Cell Research:

[4]

  • Cell lines: Retinal pigment epithelial (RPE) cells
  • Concentrations: 10 μM
  • Incubation Time: 24 h
  • Method:

    Cells are exposed to H2O2 (200 µM) for 1 hour and either pre-or post treated with 8-OH DPAT (10 µM) for 24 hours. In the case of pretreatment all measurements are made 24 hr after H2O2 and for post treatment 8-OH DPAT is added immediately following H2O2 exposure. 5HT1A agonist treatment: To assess the ability of the 5-HT1A receptor agonist, 8-OH DPAT, to reduce lipofuscin formation in cultured RPE cells, this compound is added to the culture medium every 48 hours at concentrations ranging from 0.1 to 20 µM. All experiments are undertaken in basal medium, and cells receiving vehicle alone (PBS) acted as negative controls. To determine if the effect of 8-OH DPAT is sustained following discontinuation of 5-HT1A receptor agonist treatment, 8-OH DPAT treatment is discontinued after 28 days and the cells maintained in basal medium or fed POS for a further 28 days. To assess the ability of 8-OH DPAT to remove existing lipofuscin, autophagy-derived lipofuscin and phagocytic-derived lipofuscin are allowed to accumulate as described above and then 8-OH DPAT is added every second day for up to 28 days. To confirm that 8-OH DPAT is acting via the 5-HT1A receptor agonist we include the 5-HT1A receptor antagonist S(-)-UH-301 at 5 µM in some experiments. To determine the effect of timing of 8-OH DPAT treatment on oxidative stress markers, RPE cultures are either pre-treated with 8-OH DPAT (at 1 or 10 µM) for 3 or 24 hours prior to exposure to 200 µM H2O2 for 1 hour or treated with the 5HT1A agonist for 3 or 24 hours post-exposure to H2O2. Cells not exposed to oxidative stressor serve as a negative control, and cells exposed to oxidative stressor but not 8-OH DPAT serve as a positive control. Cells exposed to 8-OH DPAT only act as an additional control.

Animal Research:

[2]

  • Animal Models: Male Lister hooded rats
  • Dosages: 0, 3.0, 10, 100 and 300 μg/kg
  • Administration: i.p.

Solubility (25°C)

In vitro

DMSO 49 mg/mL
(198.07 mM)
Ethanol 49 mg/mL
(198.07 mM)
Water Insoluble

Chemical Information

Molecular Weight 247.38
Formula

C16H25NO

CAS No. 78950-78-4
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCCN(CCC)C1CCC2=C(C1)C(=CC=C2)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy 8-OH-DPAT (8-Hydroxy-DPAT) | 8-OH-DPAT (8-Hydroxy-DPAT) supplier | purchase 8-OH-DPAT (8-Hydroxy-DPAT) | 8-OH-DPAT (8-Hydroxy-DPAT) cost | 8-OH-DPAT (8-Hydroxy-DPAT) manufacturer | order 8-OH-DPAT (8-Hydroxy-DPAT) | 8-OH-DPAT (8-Hydroxy-DPAT) distributor